Skip to content

Enzo Life Sciences

Active
Private limited companyfounded 199629 years activeLouizalaan 65, 1050 Elsene, BelgiumKBO/BCE: BE 0459.284.211
Summary

The computed 12-month bankruptcy probability of Enzo Life Sciences is 3.2% (moderate). The 2025 annual accounts show negative equity (-€1.0m) and a net result of -€185,783. Equity is shrinking by ~21.1% per year across the filed fiscal years. Its solvency ranks better than 5% of 6,055 sector peers (NACE 46, fiscal year 2025). The company has been active since 1996 and the Belgian State Gazette contains no insolvency or warning signals.

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
€814,945turnover 2025
Staff
1 FTE
Equity
-€1.0m
Loss
-€185,783
Financial health
48 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
3.2%
Structure
Parent
Enzo Biochem Inc
Auditor: Moore AuditAccounts 45 days early1 of 12 deeds read
Why 48- Negative equity -€1.0m- Loss of €185,783, the second in a row (FY 2025)+ Size: turnover €814,945, 1 FTE, total assets €142,693+ Liquidity: current ratio 1.43, cash €30,055Show the evidence

Checked score

Score 2025
48 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 15% of its sector peers (NACE 46, micro)
Financial strength · tick = 2024
Weak
Solvency 0=
equity -722.6% of total assets
Liquidity 39-21
short-term debt 70.0% · cash 21.1%
Profitability 0=
return on assets -130.2%
Bankruptcy probability, 12 months
3.2% Moderate
0%0.5%1.5%4%10%≥ 25%

About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (26,860 companies)
Last 24 months 11-2024: 4.1%highest value 12-2024: 4.1%● unchanged vs 11-2024 01-2025: 4.0%▼ -0.1 percentage points vs 12-2024 02-2025: 3.1%▼ -0.9 percentage points vs 01-2025 03-2025: 3.1%● unchanged vs 02-2025 04-2025: 3.1%● unchanged vs 03-2025 05-2025: 3.1%● unchanged vs 04-2025 06-2025: 3.1%● unchanged vs 05-2025 07-2025: 3.1%● unchanged vs 06-2025 08-2025: 3.1%● unchanged vs 07-2025 09-2025: 3.1%● unchanged vs 08-2025 10-2025: 3.0%▼ -0.1 percentage points vs 09-2025 11-2025: 3.1%▲ +0.1 percentage points vs 10-2025 12-2025: 3.0%▼ -0.1 percentage points vs 11-2025 01-2026: 3.0%● unchanged vs 12-2025lowest value 02-2026: 3.4%▲ +0.4 percentage points vs 01-2026 03-2026: 3.4%● unchanged vs 02-2026 04-2026: 3.4%● unchanged vs 03-2026 05-2026: 3.4%● unchanged vs 04-2026 06-2026: 3.4%● unchanged vs 05-2026 07-2026: 3.4%● unchanged vs 06-2026 08-2026: 3.3%▼ -0.1 percentage points vs 07-2026 09-2026: 3.3%● unchanged vs 08-2026 10-2026: 3.2%▼ -0.1 percentage points vs 09-2026
No credit on open account
Liquidity tight (current ratio 1.43 against 7.73 in 2024; short-term debt: 70% and cash: 21.1% of total assets), and equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 6% on solvency, 36% on liquidity, 6% on profitability and 11% on growth.

The bankruptcy probability was computed on 07-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals.
−lowers risk+raises risk○neutral
raises risk · Negative equity -€1.0m
NBB · annual accounts
raises risk · Loss of €185,783, the second in a row (FY 2025)
NBB · annual accounts
lowers risk · Size: turnover €814,945, 1 FTE, total assets €142,693
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
lowers risk · Liquidity: current ratio 1.43, cash €30,055
NBB · annual accounts
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
19202122232425
2019 to 2025 · latest year -€1.0m
neutral · Latest accounts filed on time
The financial year that closed on 31-07-2025 was due by 28-02-2026 and was filed on 14-01-2026, 45 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
45 days early
2024
46 days early
2023
37 days early
2022
5 days early
2021
49 days early
2020
44 days early
2019
22 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 35 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-07-2026 and is due by 28-02-2027. Nothing is late today. Usually files around 14 January (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
31-07-2026 close08-10-2026 today28-02-2027 deadline
neutral · No strike-offs in the KBO publications
Checked from 2021 on.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · full…
  2. Reappointment: Moore Audit BV (statutory auditor)Permanent representative: Sam Kwanten ·…
  3. Weakest financial yearnet -€185,783

Key points

  • Risk: Negative equityfiscal year 2025: debts exceed assets -€1.0m View
  • Risk: 7 loss-making years in a rowloss fiscal year 2025 -€185,783 View
  • Caution: Turnover fell in 2025from €2.2m to €814,945 ▼ 62.6% View
  • Caution: Among the weakest 5% on solvencysector median 45.6% · 6,055 companies -722.6% View
  • Positive: Always filed on timeaccounts within the deadline every year 8 years View
  • Controlled by Enzo Biochem Inc parent View

By topic

Financials

Fiscal year
2025
Turnover
€814,945
Loss
-€185,783
Solvency
-722.6%
Turnover▼ 62.6%
Net result
20192025
Go to Financials

Timeline

Events
13
Since
2017
Next accounts
by 28-02-2027
  1. 13-01-2025Annual accounts filed
  2. 31-07-2024Liquidity times 28
  3. 23-01-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
25-11-1996
Year ends
31-07
Peppol
Not found in the Peppol directory
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.